Hepatitis C and the risk of cardiovascular disease: An evolving epidemic?

Expert Review of Cardiovascular Therapy

Volumn 4, Issue 4, 2006, Pages 439-442

  Aytaman, Ayse ^a   McFarlane, Samy I ^b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b SUNY DOWNSTATE MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; ALPHA INTERFERON; INSULIN; TUMOR NECROSIS FACTOR ALPHA;

AGING; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; EDITORIAL; ENDOTHELIUM LESION; EPIDEMIC; FATTY LIVER; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RESISTANCE; LIFESTYLE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; OXIDATIVE STRESS; PATHOGENESIS; PREVALENCE; SMOKING;

CARDIOVASCULAR DISEASES; COMORBIDITY; DIABETES MELLITUS; DISEASE OUTBREAKS; HEPATITIS C; HUMANS; INSULIN RESISTANCE; RISK FACTORS;

EID: 33748107496     PISSN: 14779072     EISSN: 17448344     Source Type: Journal    
DOI: 10.1586/14779072.4.4.439     Document Type: Editorial

References (30)

1. SoRelle R. Global epidemic of cardiovascular disease expected by the year 2050. Circulation 100(20), e101 (1999).
2. Weinehall L. The emerging epidemic of cardiovascular disease. Scand. J. Public Health Suppl. 61, 5-8 (2003).
3. Yusuf S, Ounpuu S, Anand S. The global epidemic of atherosclerotic cardiovascular disease. Med. Princ. Pract. 11 (Suppl. 2), 3-8 (2002).
4. Bonow RO, Gheorghiade M. The diabetes epidemic: a national and global crisis. Am. J. Med. 116(Suppl. 5A), 2S-10S (2004).
5. McFarlane SI, Castro J, Kaur J et al. Control of blood pressure and other cardiovascular risk factors at different practice settings: outcomes of care provided to diabetic women compared to men. J. Clin. Hypertens. (Greenwich) 7(2), 73-80 (2005).
6. McFarlane SI, Sowers JR. Gender disparities in the control of cardiovascular risk factors in people with diabetes. J. Clin. Hypertens. (Greenwich) 7(7), 383-385 (2005).
7. Butt AA. Hepatitis C virus infection: the new global epidemic. Expert Rev. Anti Infect Ther. 3(2), 241-249 (2005).
8. Hamlyn AN. Hepatitis C: tackling the silent epidemic. Br. J. Hosp. Med. (Lond.) 66(10), 579-582 (2005).
9. Wolfe GS. Hepatitis C: the latest epidemic. Lippincotts Case Manag. 10(1), 56-59 (2005).
10. Bahtiyar G, Shin JJ, Aytaman A, Sowers JR, McFarlane SI. Association of diabetes and hepatitis C infection: epidemiologic evidence and pathophysiologic insights. Curr. Diab. Rep. 4(3), 194-198 (2004).
11. Allison ME Wreghitt T, Palmer CR, Alexander GJ. Evidence for a link between hepatitis C virus infection and diabetes mellitus in a cirrhotic population. J. Hepatol, 21(6), 1135-1139 (1994).
12. Virseda Chamorro I, Virseda Chamorro M, Prieto Carbajo RL, Jaqueti Aroca J. Hepatitis C as a risk factor of diabetes mellitus Type 2. Rev. Clin. Esp. 206(4), 167-171 (2006).
13. Kawaguchi T, Nagao Y, Tanaka K et al. Causal relationship between hepatitis C virus core and the development of Type 2 diabetes mellitus; in a hepatitis C virus hyperendemic area: a pilot study. Int. J. Mol. Med. 16(1), 109-114 (2005).
14. Yazicioglu G, Isitan F, Altunbas H et al. Insulin resistance in chronic hepatitis C. Int. J. Clin. Pract. 58(11), 1020-1022 (2004).
15. Aytug S, Reich D, Sapiro LE, Bernstein D, Begum N. Impaired IRS-1/ P13-kinase signaling in patients with HCV: a mechanism for increased prevalence of Type 2 diabetes. Hepatology 38(6), 1384-1392 (2003).
16. Maeno T, Okumura A, Ishikawa T et al. Mechanisms of increased insulin resistance in non-cirrhotic patients with chronic hepatitis C virus infection. J. Gastroenterol, Hepatol. 18(12), 1358-63 (2003).
17. Aytaman A, Bahtiyar G, McFarlane S. Interferon-a therapy and Type 1 diabetes mellitus in patients with hepatitis C: pathophysiologic insights. Therapy 2(No. 3), 439-446 (2005).
18. Ishizaka Y, Ishizaka N, Takahashi E et al. Association between hepatitis C virus core protein and carotid atherosclerosis. Circ. J. 67(1), 26-30 (2003).
19. Tomiyama H, Arai T, Hirose K, Hori S, Yamamoto Y, Yamashina A. Hepatitis C virus seropositivity, but not hepatitis B virus carrier or seropositivity, associated with increased pulse wave velocity. Atherosclerosis 166(2), 401-403 (2003).
20. Bahtiyar G, Aytaman A, Arora S, Joseph LA, Sowers RJ, McFarlane SI. Chronic hepatitis C infection increases the risk of cardiovascular disease among men independent of Type 2 diabetes. Endocrine Soc. (2005).
21. Lecube A, Hernandez C, Genesca J, Simo R. Proinflammatory cytokines, insulin resistance, and insulin secretion in chronic hepatitis C patients: a case-control study. Diabetes Care 29(5), 1096-101 (2006).
22. Koike K, Miyoshi H. Oxidative stress and hepatitis C vital infection. Hepatol. Res. (2005).
23. Ramesh S, Sanyal AJ. Hepatitis C and nonalcoholic fatty liver disease. Semin. Liver Dis. 24(4), 399-413 (2004).
24. Santoliquido A, Di Campli C, Miele L et al. Hepatic steatosis and vascular disease. Eur. Rev. Med. Pharmacol, Sci. 9(5), 269-271 (2005).
25. Valenti L, Pulixi E, Fracanzani AL et al. TNFα genotype. affects TNFα release, insulin sensitivity and the severity of liver disease in HCV chronic hepatitis. J. Hepatol. 43(6), 944-950 (2005).
26. Fukui M, Kitagawa Y, Nakamura N, Yoshikawa T. Hepatitis C virus and atherosclerosis in patients with Type 2 diabetes. JAMA 289(10), 1245-1246 (2003).
27. Volzke H, Schwahm C, Wolff B et al. Hepatitis B and C virus infection and the risk of atherosclerosis in a general population. Atherosclerosis 174(1), 99-103 (2004).
28. Marchesini G, Ronchi M, Forlani G et al. Cardiovascular disease in cirrhosis - a point-prevalence study in relation to glucose tolerance. Am. J. Gastroenterol. 94(3), 655-662 (1999).
29. Bilora F, Rinaldi R, Boccioletti V, Petrobelli F, Girolami A. Chronic viral hepatitis: a prospective factor against atherosclerosis. A study with echo-color Doppler of the carotid and femoral arteries and the abdominal aorta. Gastroenterol. Clin. Biol. 26(11), 1001-1004 (2002).
30. Feely J, Barry M, Keeling PW, Weir DG, Cooke T. Lipoprotein(a) in cirrhosis. BMJ 304(6826), 545-546 (1992).